Correction: Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress

Yu-Chin Lin¹,²,³, Meng-Hsuan Wu¹,*, Tzu-Tang Wei¹,*, Yun-Chieh Lin¹,*, Wen-Chih Huang⁴, Liang-Yu Huang¹, Yi-Ting Lin¹, and Ching-Chow Chen¹

¹ Graduate Institute of Pharmacology, National Taiwan University College of Medicine;
² Department of Oncology, National Taiwan University Hospital;
³ Department of Internal Medicine and
⁴ Department of Pathology, Far-Eastern Memorial Hospital;
* Equal contribution to work

Published:

Copyright: Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

These articles have been corrected: The proper images for Figure 3 and Figure 4 are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.


Figure 3: AMPK activation mediated dasatinib-induced ER stress and EGFR degradation. (A) The effect of dasatinib on AMPK activation. Cells were treated with dasatinib (1uM) for indicated intervals. The expression of p-AMPK and AMPK was evaluated. (B) The effect of AMPK knockdown on dasatinib-induced EGFR degradation and ER stress. Cells were treated with control or AMPK siRNA and then with dasatinib for 24 hours. (C) The effect of AMPK activation on dasatinib-induced EGFR degradation. Cells were treated with dasatinib with or without AICAR (10uM) for 24 hours. The expression of EGFR p-eIF2α, and AMPK was evaluated. (D) The correlation between p-AMPK and EGFR expression. Left, the expression of EGFR, p-AMPK, and AMPK in HNSCC cells. Right, the correlation of p-AMPK and EGFR expression in resected human specimens. Pearson’s correlation coefficient=0.659; *, p<0.01.
Figure 4: Dasatinib induced cellular ATP decrease and PDK4 up-regulation. (A,B) The effect of 6-hr or 18-hr dasatinib (1uM) on cellular ATP (A) and glucose (B) levels. *, p<0.05. (C) The expression of PDK4 and p-Erk in HNSCC cells treated with dasatinib (1uM) for indicated intervals.